Rocket Pharmaceuticals, Inc.

Equities

RCKT

US77313F1066

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:35:07 2024-04-26 pm EDT			5-day change	1st Jan Change
22.01 ^USD	-0.41%		-3.25%	-26.39%

Apr. 16	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT
Apr. 11	Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	MT

ROCKET PHARMACEUTICALS, INC. : Other Events (form 8-K)

May 01, 2020 at 06:39 am EDT

Item 8.01 Other Events.

On April 28, 2020, Rocket Pharmaceuticals, Inc. (the "Company") received written notice from the Nasdaq Stock Market informing the Company that it has regained compliance with Nasdaq Listing Rule 5605(c)(2)(A) as a result of the appointment of Dr. Elisabeth Björk to the Company's audit committee and board of directors, as reported on a Current Report on Form 8-K filed with the Securities and Exchange Commission on April 22, 2020.

--------------------------------------------------------------------------------

Latest news about Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11	MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	Apr. 02	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	Apr. 02	MT
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	Apr. 02	CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	Mar. 26	MT
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	Mar. 26	CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	Mar. 26	CI
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating	Mar. 01	MT
Rocket Pharmaceuticals Q4 Loss Narrows	Feb. 26	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 25	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	Feb. 13	MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi	Feb. 13	DJ
Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi? (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)	Feb. 13	CI
Transcript : Rocket Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM	Jan. 08
Certain Common Stock of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Warrants of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Restricted Stock Units of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Certain Stock Options of Rocket Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2023.	Dec. 12	CI
Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director	Dec. 12	CI
Rocket Pharmaceuticals Insider Sold Shares Worth $450,646, According to a Recent SEC Filing	Nov. 17	MT
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 05	CI
Cantor Fitzgerald Initiates Rocket Pharmaceuticals With Overweight Rating, Price Target is $65	23-10-24	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $315,744, According to a Recent SEC Filing	23-10-03	MT

Chart Rocket Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.1 USD

Average target price

50.31 USD

Spread / Average Target

+127.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ROCKET PHARMACEUTICALS, INC.	-26.39%	2B
VERTEX PHARMACEUTICALS INCORPORATED	-2.35%	103B
REGENERON PHARMACEUTICALS, INC.	+0.66%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-16.96%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.49%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.35%	13.86B
SAREPTA THERAPEUTICS, INC.	+34.30%	12.04B

Bio Therapeutic Drugs